Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

Considerable evidence has accumulated indicating that the multidrug transporter or P-glycoprotein plays a role in the development of simultaneous resistance to multiple cytotoxic drugs in cancer cells. In recent years, various approaches such as mutational analyses and biochemical and pharmacological characterization have yielded significant information about the relationship of structure and function of P-glycoprotein. However, there is still considerable controversy about the mechanism of action of this efflux pump and its function in normal cells. This review summarizes current research on the structure-function analysis of P-glycoprotein, its mechanism of action, and facts and speculations about its normal physiological role.

[1]  W. Hait,et al.  Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. , 1989, Molecular pharmacology.

[2]  P. Gros,et al.  Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. , 1993, Biochemistry.

[3]  I. Pastan,et al.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. , 1998, Biochemistry.

[4]  M. Azzaria,et al.  Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance , 1989, Molecular and cellular biology.

[5]  E. Schuetz,et al.  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.

[6]  T. Gant,et al.  Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. , 1996, British Journal of Cancer.

[7]  J. Beijnen,et al.  Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. , 1996, Journal of the National Cancer Institute.

[8]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[9]  M. Gottesman,et al.  Interaction of bioactive hydrophobic peptides with the human multidrug transporter , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  J. Ford.  Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. , 1996, European journal of cancer.

[11]  M. Kool,et al.  Peptide transport by the multidrug resistance protein MRP1. , 2001, Cancer research.

[12]  D. Clarke,et al.  Rapid Purification of Human P-glycoprotein Mutants Expressed Transiently in HEK 293 Cells by Nickel-Chelate Chromatography and Characterization of their Drug-stimulated ATPase Activities (*) , 1995, The Journal of Biological Chemistry.

[13]  P. Borst,et al.  Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease , 1993, Cell.

[14]  J. Neefjes,et al.  Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. , 1996, British Journal of Cancer.

[15]  P A Insel,et al.  Beta-adrenergic receptors and receptor signaling in heart failure. , 1999, Annual review of pharmacology and toxicology.

[16]  I. Pastan,et al.  Analysis of random recombination between human MDR1 and mouse mdr1a cDNA in a pHaMDR-dihydrofolate reductase bicistronic expression system. , 1998, Molecular pharmacology.

[17]  A. E. Senior,et al.  The catalytic cycle of P‐glycoprotein , 1995, FEBS letters.

[18]  P. Gros,et al.  Functional Dissection of P-glycoprotein Nucleotide-binding Domains in Chimeric and Mutant Proteins , 1995, The Journal of Biological Chemistry.

[19]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[20]  I. Pastan,et al.  Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. , 1998, Biochemistry.

[21]  I. Pastan,et al.  The multidrug transporter, a double-edged sword. , 1988, The Journal of biological chemistry.

[22]  M. Gottesman,et al.  KT-5720 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human MDR1 cDNA and in human multidrug-resistant carcinoma cells. , 1995, European journal of cancer.

[23]  T. Tsuruo,et al.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Rosenberg,et al.  Intronic Enhancer Activity of the Eosinophil-derived Neurotoxin (RNS2) and Eosinophil Cationic Protein (RNS3) Genes Is Mediated by an NFAT-1 Consensus Binding Sequence* , 1997, The Journal of Biological Chemistry.

[25]  F. Sharom,et al.  Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. , 1996, Biochemistry.

[26]  P. Roepe,et al.  Biophysical aspects of P-glycoprotein-mediated multidrug resistance. , 1997, International review of cytology.

[27]  K. Ueda,et al.  Amino acid substitutions in the first transmembrane domain (TM1) of P‐glycoprotein that alter substrate specificity , 1997, FEBS letters.

[28]  W. T. Beck,et al.  Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. , 1988, Biochemical and biophysical research communications.

[29]  Piet Borst,et al.  Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein , 1996, British journal of pharmacology.

[30]  M. Raschack,et al.  Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. , 1995, Biochemical pharmacology.

[31]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[32]  I. Pastan,et al.  Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. , 1990, The Journal of biological chemistry.

[33]  P. Gros,et al.  Phosphatidylcholine translocase: A physiological role for the mdr2 gene , 1994, Cell.

[34]  R. Fine,et al.  Partial Inhibition of Multidrug Resistance by Safingol Is Independent of Modulation of P-glycoprotein Substrate Activities and Correlated with Inhibition of Protein Kinase C (*) , 1995, The Journal of Biological Chemistry.

[35]  E. Goormaghtigh,et al.  Secondary and Tertiary Structure Changes of Reconstituted P-glycoprotein , 1996, The Journal of Biological Chemistry.

[36]  P. Borst,et al.  Multidrug resistance and the role of P-glycoprotein knockout mice. , 1995, European journal of cancer.

[37]  C. Higgins,et al.  The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. , 1997, Biochimica et biophysica acta.

[38]  D. Housman,et al.  Isolation and expression of a complementary DNA that confers multidrug resistance , 1986, Nature.

[39]  F. Sharom,et al.  Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. , 1993, The Journal of biological chemistry.

[40]  F. Sharom,et al.  Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. , 1996, The Biochemical journal.

[41]  M C Willingham,et al.  Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. , 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[42]  T. Kwan,et al.  Mutational analysis of the P-glycoprotein first intracellular loop and flanking transmembrane domains. , 1998, Biochemistry.

[43]  V. Ling,et al.  Sex‐dependent and independent expression of the P‐glycoprotein isoforms in Chinese hamster , 1990, Journal of cellular physiology.

[44]  M C Willingham,et al.  Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[45]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[46]  V. Ling,et al.  Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. , 1997, European journal of biochemistry.

[47]  L. Mir,et al.  Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model. , 1997, European journal of biochemistry.

[48]  I. Pastan,et al.  Pseudomonas exotoxin fusion proteins are potent immunogens for raising antibodies against P-glycoprotein. , 1991, BioTechniques.

[49]  M. Whiteway,et al.  Functional complementation of yeast ste6 by a mammalian multidrug resistance mdr gene. , 1992, Science.

[50]  L. Greenberger,et al.  Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. , 1993, The Journal of biological chemistry.

[51]  T. Litman,et al.  pH Regulation in Sensitive and Multidrug Resistant Ehrlich Ascites Tumor Cells , 1998, Cellular Physiology and Biochemistry.

[52]  I. Pastan,et al.  Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. , 1988, Molecular pharmacology.

[53]  I. Pastan,et al.  Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. , 1986, The Journal of biological chemistry.

[54]  I. Pastan,et al.  Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[55]  T. Kwan,et al.  Mutagenesis of transmembrane domain 11 of P-glycoprotein by alanine scanning. , 1996, Biochemistry.

[56]  S. Devine,et al.  Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Snyder,et al.  The pineal gland and melatonin: molecular and pharmacologic regulation. , 1999, Annual review of pharmacology and toxicology.

[58]  F. Sharom,et al.  The effects of lipids and detergents on ATPase-active P-glycoprotein. , 1993, Biochimica et biophysica acta.

[59]  B. Sankaran,et al.  P-glycoprotein Is Stably Inhibited by Vanadate-induced Trapping of Nucleotide at a Single Catalytic Site (*) , 1995, The Journal of Biological Chemistry.

[60]  I. Roninson,et al.  An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene , 1988, Cell.

[61]  A. Puga,et al.  Regulation of gene expression by reactive oxygen. , 1999, Annual review of pharmacology and toxicology.

[62]  B. Sankaran,et al.  Inhibition of P-glycoprotein ATPase activity by procedures involving trapping of nucleotide in catalytic sites. , 1997, Archives of biochemistry and biophysics.

[63]  P. Roepe,et al.  Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. , 1993, Biochemistry.

[64]  S. Kane,et al.  Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein. , 1997, Biochemistry.

[65]  S. Ambudkar,et al.  Purification and reconstitution of human P-glycoprotein. , 1998, Methods in enzymology.

[66]  G. Raghu,et al.  Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. , 1996, Experimental hematology.

[67]  M. Gottesman,et al.  Is the multidrug transporter a flippase? , 1992, Trends in biochemical sciences.

[68]  W. Stein,et al.  Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. , 1997, Physiological reviews.

[69]  Carol L. Williams,et al.  Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. , 1989, The Journal of biological chemistry.

[70]  V. Ling,et al.  P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. , 1997, European journal of biochemistry.

[71]  P. Borst,et al.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[72]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[73]  M. Borgnia,et al.  Competition of Hydrophobic Peptides, Cytotoxic Drugs, and Chemosensitizers on a Common P-glycoprotein Pharmacophore as Revealed by Its ATPase Activity (*) , 1996, The Journal of Biological Chemistry.

[74]  K Ueda,et al.  P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. , 1989, Biochemical and biophysical research communications.

[75]  A. Schinkel,et al.  The physiological function of drug-transporting P-glycoproteins. , 1997, Seminars in cancer biology.

[76]  P. Gros,et al.  Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites. , 1998, Biochemistry.

[77]  I. Pastan,et al.  A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[78]  I. Pastan,et al.  Characterization of the azidopine and vinblastine binding site of P-glycoprotein. , 1992, The Journal of biological chemistry.

[79]  I. Pastan,et al.  Characterization of Phosphorylation-defective Mutants of Human P-glycoprotein Expressed in Mammalian Cells (*) , 1996, The Journal of Biological Chemistry.

[80]  J. Balsinde,et al.  Regulation and inhibition of phospholipase A2. , 1999, Annual review of pharmacology and toxicology.

[81]  R. Campbell,et al.  The Groove between the α- and β-Subunits of Hormones with Lutropin (LH) Activity Appears to Contact the LH Receptor, and Its Conformation Is Changed during Hormone Binding (*) , 1995, The Journal of Biological Chemistry.

[82]  A. E. Senior,et al.  ATP hydrolysis by multidrug-resistance protein from Chinese hamster ovary cells , 1995, Journal of Bioenergetics and Biomembranes.

[83]  I. Pastan,et al.  Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. , 1994, Molecular pharmacology.

[84]  Jie Liu,et al.  Metallothionein: an intracellular protein to protect against cadmium toxicity. , 1999, Annual review of pharmacology and toxicology.

[85]  P. Houghton,et al.  Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines. , 1990, Cancer communications.

[86]  R. Dingledine,et al.  Genetic regulation of glutamate receptor ion channels. , 1999, Annual review of pharmacology and toxicology.

[87]  C. Higgins,et al.  Structure of the Multidrug Resistance P-glycoprotein to 2.5 nm Resolution Determined by Electron Microscopy and Image Analysis* , 1997, The Journal of Biological Chemistry.

[88]  B. Sikic,et al.  Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein , 1997, Cancer Chemotherapy and Pharmacology.

[89]  I. Pastan,et al.  Fluorescent cellular indicators are extruded by the multidrug resistance protein. , 1993, The Journal of biological chemistry.

[90]  J. Beijnen,et al.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. , 1997, The Journal of clinical investigation.

[91]  I. Pastan,et al.  Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. , 1998, Biochemistry.

[92]  I. Pastan,et al.  Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. , 1994, Molecular pharmacology.

[93]  D. Clarke,et al.  Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. , 1994, The Journal of biological chemistry.

[94]  I. Pastan,et al.  Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. , 1996, Molecular biology of the cell.

[95]  R. Schimke,et al.  Peptide transport by the multidrug resistance pump. , 1992, The Journal of biological chemistry.

[96]  B. Sikic,et al.  Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins* , 1997, The Journal of Biological Chemistry.

[97]  J. M. Ford,et al.  Pharmacology of drugs that alter multidrug resistance in cancer. , 1990, Pharmacological reviews.

[98]  M. Gottesman,et al.  HIV-1 protease inhibitors and the MDR1 multidrug transporter. , 1998, The Journal of clinical investigation.

[99]  A. E. Senior,et al.  Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein. , 1995, Archives of biochemistry and biophysics.

[100]  I. Pastan,et al.  Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression. , 1993, The Journal of biological chemistry.

[101]  P. Roepe,et al.  Are altered pHi and membrane potential in hu MDR 1 transfectants sufficient to cause MDR protein-mediated multidrug resistance? , 1996, The Journal of general physiology.

[102]  I. Pastan,et al.  Mechanism of Action of Human P-glycoprotein ATPase Activity , 1998, The Journal of Biological Chemistry.

[103]  V. Ling,et al.  Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. , 1997, Biochemical pharmacology.

[104]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[105]  V. Ling,et al.  ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. , 1994, The Journal of biological chemistry.

[106]  T. Tsuruo,et al.  Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. , 1996, AIDS research and human retroviruses.

[107]  F. Sharom,et al.  Interaction of the P-glycoprotein Multidrug Transporter with Peptides and Ionophores (*) , 1995, The Journal of Biological Chemistry.

[108]  L. Greenberger,et al.  Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b. , 1991, The Journal of biological chemistry.

[109]  W. T. Beck,et al.  Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. , 1990, Advances in enzyme regulation.

[110]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[111]  T. Tsuruo,et al.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. , 1988, Cancer research.

[112]  S. Ambudkar,et al.  Relation Between the Turnover Number for Vinblastine Transport and for Vinblastine-stimulated ATP Hydrolysis by Human P-glycoprotein* , 1997, The Journal of Biological Chemistry.

[113]  I. Pastan,et al.  Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters. , 1992, The Journal of biological chemistry.

[114]  S. Zhao,et al.  Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. , 1992, Blood.

[115]  I. Pastan,et al.  Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. , 1992, Science.

[116]  D. Housman,et al.  The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues , 1989, Molecular and cellular biology.

[117]  D. Clarke,et al.  Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. , 1994, Biochemistry.

[118]  P. Melera,et al.  Mutations in the sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporin A reversal. , 1997, Molecular pharmacology.

[119]  I. Pastan,et al.  Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia , 1989, Molecular and cellular biology.

[120]  S. Ambudkar.  Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. , 1998, Methods in enzymology.

[121]  D. Clarke,et al.  Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. , 1994, The Journal of biological chemistry.

[122]  A. Brossi,et al.  The nitrogen of the acetamido group of colchicine modulates P-glycoprotein-mediated multidrug resistance. , 1993, Biochemistry.

[123]  I. Tamai,et al.  Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. , 1991, The Journal of biological chemistry.

[124]  I. Pastan,et al.  Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. , 1995, Cancer research.

[125]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[126]  I. Pastan,et al.  Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[127]  S. Cole,et al.  Function, evolution and structure of multidrug resistance protein (MRP). , 1997, Seminars in cancer biology.

[128]  J. Riordan,et al.  Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1. , 1994, The Journal of biological chemistry.

[129]  V. Ling,et al.  Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein. , 1998, European journal of biochemistry.

[130]  P. Gros,et al.  Functional expression of P-glycoproteins in secretory vesicles. , 1994, The Journal of biological chemistry.

[131]  I. Roninson,et al.  Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.

[132]  Y. Assaraf,et al.  Functional Reconstitution of P-glycoprotein Reveals an Apparent Near Stoichiometric Drug Transport to ATP Hydrolysis (*) , 1996, The Journal of Biological Chemistry.

[133]  M. Ochocka,et al.  Is P-glycoprotein a sufficient marker for multidrug resistance in vivo? Immunohistochemical staining for P-glycoprotein in children and adult leukemia: correlation with clinical outcome. , 1995, Leukemia & lymphoma.

[134]  H L Pearce,et al.  Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. , 1988, Molecular pharmacology.

[135]  Piet Borst,et al.  MDR1 P-Glycoprotein Is a Lipid Translocase of Broad Specificity, While MDR3 P-Glycoprotein Specifically Translocates Phosphatidylcholine , 1996, Cell.

[136]  P. Roepe,et al.  The role of the MDR protein in altered drug translocation across tumor cell membranes. , 1995, Biochimica et biophysica acta.

[137]  I. Pastan,et al.  Genetic analysis of the multidrug transporter. , 1995, Annual review of genetics.

[138]  U. Germann,et al.  P-glycoprotein--a mediator of multidrug resistance in tumour cells. , 1996, European journal of cancer.

[139]  D. Housman,et al.  The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[140]  U. S. Rao,et al.  Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. , 1995 .

[141]  G Ecker,et al.  Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. , 1996, Molecular pharmacology.

[142]  D. Gadsby,et al.  ATP hydrolysis cycles and mechanism in P-glycoprotein and CFTR. , 1997, Seminars in cancer biology.

[143]  H L Pearce,et al.  Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[144]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[145]  D. Clarke,et al.  Covalent Modification of Human P-glycoprotein Mutants Containing a Single Cysteine in Either Nucleotide-binding Fold Abolishes Drug-stimulated ATPase Activity (*) , 1995, The Journal of Biological Chemistry.

[146]  M. Gottesman,et al.  Altered Drug-stimulated ATPase Activity in Mutants of the Human Multidrug Resistance Protein (*) , 1996, The Journal of Biological Chemistry.

[147]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[148]  V. Ling,et al.  Reconstitution of Drug Transport by Purified P-glycoprotein (*) , 1995, The Journal of Biological Chemistry.

[149]  S. Amara,et al.  Excitatory amino acid transporters: a family in flux. , 1999, Annual review of pharmacology and toxicology.

[150]  P. Borst,et al.  What have we learnt thus far from mice with disrupted P-glycoprotein genes? , 1996, European journal of cancer.

[151]  B. Sankaran,et al.  Both P-glycoprotein Nucleotide-binding Sites Are Catalytically Active (*) , 1995, The Journal of Biological Chemistry.

[152]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[153]  A. E. Senior,et al.  Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. , 1994, Biochemistry.

[154]  P. Gros,et al.  A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[155]  S. Hegewisch-Becker,et al.  Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. , 1995, Gene therapy.

[156]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[157]  S. Ambudkar.  Purification and reconstitution of functional human P-glycoprotein , 1995, Journal of bioenergetics and biomembranes.

[158]  M. Gottesman,et al.  The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi‐drug transporter , 1993, International journal of cancer.

[159]  I. Bosch,et al.  Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. , 1997, Biochemistry.

[160]  G Ecker,et al.  Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance. , 1995, Journal of medicinal chemistry.

[161]  R Hori,et al.  Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.

[162]  P. Casey,et al.  Characterization of Prenylcysteines That Interact with P-glycoprotein and Inhibit Drug Transport in Tumor Cells (*) , 1995, The Journal of Biological Chemistry.

[163]  I. Pastan,et al.  Transfer and expression of the human multiple drug resistance gene into live mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[164]  I. Pastan,et al.  ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[165]  I. Pastan,et al.  Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine. , 1989, The Journal of biological chemistry.

[166]  G. F. Ames,et al.  ATP-dependent transport systems in bacteria and humans: relevance to cystic fibrosis and multidrug resistance. , 1993, Annual review of microbiology.

[167]  I. Pastan,et al.  P-glycoprotein plays an insignificant role in the presentation of antigenic peptides to CD8+ T cells. , 1998, Cancer research.

[168]  D. Loo,et al.  Kinetics of Steady-state Currents and Charge Movements Associated with the Rat Na+/Glucose Cotransporter (*) , 1995, The Journal of Biological Chemistry.

[169]  D. Sibley,et al.  New insights into dopaminergic receptor function using antisense and genetically altered animals. , 1999, Annual review of pharmacology and toxicology.

[170]  Robert,et al.  Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. , 1989, The Journal of biological chemistry.

[171]  G. Ecker,et al.  Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein--an overview. , 1995, Wiener klinische Wochenschrift.

[172]  I. Pastan,et al.  Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. , 1990, Cancer research.

[173]  I. Pastan,et al.  Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. , 1992, Journal of the National Cancer Institute.

[174]  K. Ramos.  Redox regulation of c-Ha-ras and osteopontin signaling in vascular smooth muscle cells: implications in chemical atherogenesis. , 1999, Annual review of pharmacology and toxicology.

[175]  I. Roninson,et al.  Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185----Val-185 substitution in P-glycoprotein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[176]  S. Moncada,et al.  Inhibition of nitric oxide synthase as a potential therapeutic target. , 1999, Annual review of pharmacology and toxicology.

[177]  D. Clarke,et al.  Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. , 1993, The Journal of biological chemistry.

[178]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.